Search

Your search keyword '"Rapaccini, GL (ORCID:0000-0002-6467-857X)"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Rapaccini, GL (ORCID:0000-0002-6467-857X)" Remove constraint Author: "Rapaccini, GL (ORCID:0000-0002-6467-857X)"
25 results on '"Rapaccini, GL (ORCID:0000-0002-6467-857X)"'

Search Results

1. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

2. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel

3. SARS-CoV2 RNA detection in a pancreatic pseudocyst sample

4. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

5. ELF TEST IS A RELIABLE NON INVASIVE TEST FOR FIBROSIS IN NAFLD SUBJECTS

6. SCREENING FOR THE IDENTIFICATION OF AUTOIMMUNE OR LYMPHOPROLIFERATIVE ONSET IN PATIENTS NAiVE TO HCV ANTIVIRAL TREATMENT

7. Pilot Study on the Role of Multidisciplinary Approach in Risk Reduction of Risk of Non- alcoholic Fatty Liver in Subjects with Eating Disorders

8. Treatment of Portal Vein Tumor Thrombosis (PVTT) Can Impact Survival of Patients With Advanced HCC?

9. Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience

10. New Therapeutic Perspectives for Management of Advanced Hepatocellular Carcinoma With Hepatic Arteriovenous Fistula: Balloon-Occluded Percutaneous Radio-Frequency Thermal Ablation (RFA) Plus Transcatheter Arterial Chemoembolization (TACE)

11. Single-Step Balloon-Occluded Percutaneous Radio-Frequency Thermal Ablation (RFA) Plus Transcatheter Arterial Chemoembolization (TACE) for Treatment of 'Complex' Unresectable Hepatocellular Carcinoma

12. HCC PERSONALIZED TREATMENT IN THE MULTIMODAL MANAGEMENT ERA: THE HEPATOCAT GROUP EXPERIENCE

13. FIBROSIS PROGRESSION DURING SUNITINIB THERAPY IN CIRRHOTIC PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

14. Liver functional reserve and survival after sunitinib therapy in cirrhotic patients with advanced hepatocellular carcinoma

15. SERUM SODIUM IS A PREDICTOR OF SURVIVAL FOR 'INTERMEDIATE HCC' TREATED WITH TRANSARTERIAL CHEMIOEMBOLIZATION (TACE)

16. THE 15 AND 30 MINUTES SAMPLING OF 13C-BREATH TESTING ARE ABLE TO PREDICT SEVERE HEPATIC FIBROSIS AND SEVERITY OF LIVER DISEASE

17. PREVALENCE OF LIVER STEATOSIS AND METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS

18. Use of G-CSF during acute on chronic liver failure: Clinical and biochemical safety profile

19. CXCR4, vegfr and VLA-4 levels in peripheral blood lymphocytes of patients with acute on chronic liver failure treated with G-CSF

20. Prognosis of patients with hepatocellular carcinoma (HCC) according to Okuda staging system, CLIP staging system and BCLC staging classification: Results of a single Italian centre

21. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: Functional hepatic reserve and survival

22. Serum markers of fibrogenesis and fibrosis in nonalcoholic steatohepatitis (NASH)

23. Assessment of recent thymic emigrants (TRECs) in patients with HCV chronic hepatitis

24. Serum laminin levels in non alcoholic steatohepatitis

25. Quantitative liver function tests to assess MEHOS activity in NASH patients

Catalog

Books, media, physical & digital resources